Sampre Nutritions files FY26 annual report, sets AGM for Sep 4

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights

Sampre Nutritions Limited filed its FY26 annual report and announced its 35th AGM for September 4, 2026. The company issued a corrigendum to fix typographical errors in the AGM notice regarding scrutinizer appointment and result publication dates. The corrected report is now available for shareholders.

powered bylight_fuzz_icon
48244717

*this image is generated using AI for illustrative purposes only.

Sampre Nutritions Limited has filed its annual report for the financial year 2025-26 and issued the notice convening its Thirty-Fifth Annual General Meeting (AGM). The meeting is scheduled to be held on Friday, September 4, 2026, at 11:00 am through Video Conferencing or Other Audio-Visual Means, in accordance with applicable circulars from the Ministry of Corporate Affairs and SEBI.

The company communicated a corrigendum to members via email to rectify certain typographical errors in the dates relating to the appointment of the Scrutinizer and the publication of the AGM results. Sampre Nutritions stated that these errors were purely typographical and did not affect the substance of the Notice of AGM, the resolutions proposed, or any material information contained in the Annual Report.

The corrected Annual Report has been dispatched to members and uploaded on the company’s website. Members are requested to refer to and rely upon the corrected document for FY26.

The filing was made pursuant to Regulations 30 and 34(1) read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Brahma Gurbani, Managing Director, signed the communication dated August 14, 2026.

Historical Stock Returns for Sampre Nutritions

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-3.19%+11.18%-75.07%-72.13%+40.62%

How will the financial performance disclosed in the FY25-26 annual report influence Sampre Nutritions' dividend policy for upcoming quarters?

What strategic initiatives or capital expenditure plans are expected to be discussed or approved during the September 4, 2026 AGM?

Could the typographical errors in the AGM notice indicate broader governance or compliance risks that investors should monitor in future filings?

Sampre Nutritions Q1 Results: Net profit rises 23% YoY to ₹70.21 lakh

scanx
Reviewed by
Riya DScanX News Team
Key Highlights

Sampre Nutritions reported Q1FY27 standalone net profit of ₹70.21 lakh on revenue of ₹1,484.80 lakh. Revenue surged 36.6% YoY, while net profit remained nearly flat. The Board approved a remuneration hike for WTD Vishal Ratan Gurbani from ₹18 lakh to ₹60 lakh p.a., effective April 1, 2026, pending AGM approval.

powered bylight_fuzz_icon
47486553

*this image is generated using AI for illustrative purposes only.

Sampre Nutritions Limited reported a standalone net profit of ₹70.21 lakh for the first quarter ended June 30, 2026, compared to ₹70.94 lakh in Q1FY26. Revenue from operations rose 36.6% year-on-year to ₹1,484.80 lakh, up from ₹1,086.65 lakh in the corresponding period of the previous year. The company also posted consolidated net profit of ₹70.21 lakh, with consolidated revenue matching the standalone figure at ₹1,484.80 lakh. These results reflect improved top-line growth despite stable profit margins.

The Board of Directors approved the financial results on August 5, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The unaudited results were reviewed by the statutory auditors, N G Rao & Associates, under Standard on Review Engagements (SRE) 2410. The Board also approved the notice for the 35th Annual General Meeting (AGM) scheduled for September 4, 2026, to be held via Video Conferencing (VC) or Other Audio-Visual Means (OAVM).

Key Financial Metrics

Particulars Q1FY27 (₹ Lakh) Q1FY26 (₹ Lakh) Change
Revenue from Operations 1,484.80 1,086.65 +36.6%
Total Expenses 1,411.65 1,018.21 +38.6%
Profit Before Tax 79.88 70.94 +12.6%
Net Profit 70.21 70.94 -1.0%
EPS (Basic) ₹0.33 ₹0.34 -2.9%

Note: Consolidated figures for revenue and net profit are identical to standalone figures.

Remuneration Revision Proposal

The Board approved a proposal to increase the remuneration of Vishal Ratan Gurbani, Whole-Time Director, from ₹18,00,000 per annum to ₹60,00,000 per annum. This revision is effective from April 1, 2026, and requires approval from members at the ensuing AGM. The Nomination and Remuneration Committee recommended this change. The approval relates solely to the revision in remuneration and does not constitute a fresh appointment or re-appointment; all other terms of his existing appointment remain unchanged.

What the Numbers Show

Revenue growth outpaced expense growth slightly in absolute terms but expenses rose at a marginally higher percentage rate (38.6%) compared to revenue (36.6%). This dynamic compressed the profit before tax margin slightly, although the absolute profit before tax increased by 12.6% to ₹79.88 lakh. Employee benefits expense was a major cost driver, rising to ₹509.93 lakh from ₹316.87 lakh year-on-year, indicating potential headcount expansion or wage adjustments. Finance costs decreased significantly to ₹25.69 lakh from ₹30.81 lakh, suggesting reduced debt burden or lower interest rates.

Historical Stock Returns for Sampre Nutritions

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-3.19%+11.18%-75.07%-72.13%+40.62%

How will the significant 233% increase in the Whole-Time Director's remuneration impact shareholder sentiment and voting outcomes at the upcoming AGM?

Given that employee benefits rose by over 60%, is Sampre Nutritions expanding its workforce to support the 36.6% revenue growth, or are these costs driven by inflationary wage adjustments?

Will the slight compression in net profit margins persist in Q2FY27 as the company scales operations, or will operational efficiencies help restore profitability?

More News on Sampre Nutritions

1 Year Returns:-72.13%